The vitamin D receptor (VDR) is a crucial nuclear receptor that influences a vast array of physiological processes, including calcium homeostasis, immune function, and cell growth and differentiation. Consequently, VDR agonists have become increasingly important targets in drug discovery. Elocalcitol, a synthetic analog of vitamin D with CAS 199798-84-0, exemplifies the potential of these compounds. NINGBO INNO PHARMCHEM CO.,LTD. supports this field by providing high-quality Elocalcitol.

As a selective and potent vitamin D receptor agonist, Elocalcitol demonstrates remarkable biological activities. Its therapeutic potential is being explored in conditions where VDR signaling is dysregulated. This includes its well-documented effects on inhibiting prostate cell growth and its significant elocalcitol anti-inflammatory activity. These properties make it a valuable asset for research into cancer and inflammatory diseases.

The application of Elocalcitol in benign prostatic hyperplasia (BPH) is particularly noteworthy. By acting on the VDR, it can modulate pathways involved in prostate growth and inflammation, offering a more targeted approach to managing this common condition. Similarly, its impact on inflammatory pathways makes it a candidate for treating conditions like endometriosis. Understanding the elocalcitol 199798-84-0 properties is key for researchers investigating these therapeutic avenues.

The development and availability of these specialized compounds are facilitated by reliable chemical suppliers. For research institutions and pharmaceutical companies looking to buy elocalcitol online, NINGBO INNO PHARMCHEM CO.,LTD. provides a dependable source. Working with trusted elocalcitol manufacturers suppliers ensures the quality and consistency needed for preclinical and clinical studies.

The broader field of VDR agonists is expanding rapidly, with ongoing research into their applications for autoimmune diseases, metabolic disorders, and various cancers. Elocalcitol, with its unique profile of activity, represents a significant contribution to this expanding therapeutic landscape. Its role in elocalcitol prostate cancer inhibition further highlights its potential in oncology.

In conclusion, Elocalcitol is a prime example of how targeted research into VDR agonists can yield compounds with substantial therapeutic promise. As a critical pharmaceutical intermediate, its availability fuels innovation in understanding and treating a variety of complex diseases.